Plain-English translation of NCT07376642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing IMV101, a new experimental cell therapy designed to treat relapsed or refractory B-cell non-Hodgkin lymphoma—a type of blood cancer that has come back or stopped responding to standard treatments. Researchers want to find the safest and most effective dose of this medication, and to see whether it can help shrink tumors in people whose cancer has been difficult to control.
Many people with advanced B-cell lymphoma run out of treatment options after their cancer stops responding to or comes back after standard chemotherapy and other therapies. This trial exists to explore whether this new immunotherapy approach can offer hope to those patients.
You likely qualify if…
You likely don't qualify if…
If enrolled, you would receive a single infusion of IMV101 at the study center. The trial involves two phases: first, researchers will test increasing doses in small groups to determine safety and tolerability; then, they will expand to a larger group at the recommended dose to confirm how well the treatment works. You would have regular clinic visits for blood tests, imaging scans, and health assessments, with long-term follow-up to monitor your response to treatment and check for any delayed side effects or safety concerns.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China